

Figure S1. Luciferase expression from orthotopic pancreatic tumors after imaging of pancreas in NSG mice. Each mouse received $\sim 1 \times 10^6$ MIA PaCa-2 cells.




Figure S2. After 0.5 h and 4h of injecting micelles carrying GDC-0449 and Cy5.5-let-7b, Epi-fluorescence signal from Cy5.5-let-7 and bioluminescence signal from tumor cells were co-localized at 30 min and 4h post injection.






Figure S3: Radiance measurement Values of fluorescence signal for the IVIS images in of dissected organs after 0.08, 0.25, 1, 4, 24 h and 48 h of administration of micelles or micellar formulations.

A

Z Average (d.nm): 95 ± 10

B

Z Average (d.nm): 80 ± 10

Figure S4. Particle size distribution of GDC-0449 and Let7b loaded (A) micelles and (B) emulsion formulations.





Figure S5. Plasma toxicity profile after treatment with (A) single dose of miRNA and GDC-0449 loaded micelles (48 h) and (B) multiple dose of different micelles formulations.




Figure S6. Organ toxicity after single dose. H&E staining of vital organ slices after single intravenous injection of emulsion or micellar formulations of GDC-0449 and Cy5.5-let-7b in orthotopic pancreatic tumor-bearing NSG mice at the equivalent dose of 10 and 2 mg/kg, respectively.




Figure S7. Organ toxicity after multiple dose. H&E staining of vital organ slices after single intravenous injection of micellar formulations of GDC-0449 and let-7b into orthotopic pancreatic tumor-bearing NSG mice at the equivalent dose of 10 and 2 mg/kg, respectively.

Supplementary Table 1. Percent of injected dose (ID) of Cy5-let-7b after intravenous injection of emulsion and mPEG-b-PCC-g-DC-g-TEPA micellar formulations in orthotopic pancreatic tumor-bearing NSG mice. Results are presented as the mean \pm S.D. (n=4).

% ID emulsion						
Time	Kidney	Lung	Liver	Tumor	Heart	Spleen
0.08 h	8.20 \pm 1.49	4.82 \pm 0.44	41.20 \pm 5.55	9.38 \pm 3.32	1.14 \pm 0.13	2.25 \pm 0.44
0.25 h	7.7 \pm 99	2.42 \pm 0.74	42.39 \pm 8.98	6.23 \pm 1.26	0.91 \pm 0.17	2.93 \pm 0.32
1 h	3.38 \pm 0.25	2.89 \pm 0.31	17.13 \pm 4.97	6.80 \pm 1.04	1.75 \pm 0.59	3.06 \pm 0.1
4 h	2.54 \pm 0.74	2.17 \pm 1.15	13.76 \pm 1.12	4.92 \pm 2.39	0.96 \pm 0.45	2.13 \pm 1.23
24 h	0.35 \pm 0.02	0.42 \pm 0.2	3.78 \pm 1.14	0.62 \pm 0.37	0.12 \pm 0.02	0.18 \pm 0.03
% ID micelles						
Time	Kidney	Lung	Liver	Tumor	Heart	Spleen
0.08 h	3.33 \pm 0.23	2.84 \pm 0.34	34.51 \pm 4.55	9.30 \pm 1.63	1.81 \pm 0.22	1.30 \pm 0.45
0.25 h	6.87 \pm 2.40	2.61 \pm 0.19	38.26 \pm 6.42	10.73 \pm 2.97	1.92 \pm 0.06	2.26 \pm 0.15
1 h	9.77 \pm 0.63	2.32 \pm 0.32	35.54 \pm 3.15	10.52 \pm 1.04	2.85 \pm 0.31	3.30 \pm 0.58
4 h	9.03 \pm 0.23	2.12 \pm 0.10	34.69 \pm 4.53	17.08 \pm 1.11	1.09 \pm 0.19	2.72 \pm 0.95
24 h	7.48 \pm 0.94	1.69 \pm 0.15	15.80 \pm 0.41	5.32 \pm 1.69	1.02 \pm 0.13	1.52 \pm 0.27

Supplementary Table 2. Percent of injected dose (ID) of GDC-0449 in major tissues from tumor-bearing NSG mice intravenously administering Cy5.5-let-7b and GDC-0449 emulsion or micelles at a dose of 2 mg/kg of miRNA and 10 mg/kg GDC-0449, respectively. Results are presented as the mean \pm S.D. (n=4).

	%ID emulsion					
Time	Kidney	Lung	Liver	Tumor	Heart	Spleen
0.08 h	2.06 \pm 0.15	0.89 \pm 0.12	9.14 \pm 1.36	1.1 \pm 0.4	0.73 \pm 0.11	0.05 \pm 0.02
0.25 h	2.05 \pm 0.27	0.76 \pm 0.07	10.9 \pm 1.29	1.53 \pm 0.26	0.62 \pm 0.04	0.76 \pm 0.04
1 h	0.83 \pm 0.11	0.55 \pm 0.1	5.8 \pm 0.55	1.41 \pm 0.36	0.44 \pm 0.02	0.92 \pm 0.03
4 h	0.15 \pm 0.03	0.06 \pm 0.03	0.89 \pm 0.13	0.25 \pm 0.02	0.05 \pm 0.02	0.05 \pm 0.01
24 h	-	-	0.07 \pm 0.02	-	-	-
	%ID micelles					
Time	Kidney	Lung	Liver	Tumor	Heart	Spleen
0.08 h	0.81 \pm 0.05	0.75 \pm 0.04	4.79 \pm 0.39	1.06 \pm 0.12	0.54 \pm 0.04	0.18 \pm 0.01
0.25 h	1.60 \pm 0.37	0.74 \pm 0.14	7.16 \pm 0.86	1.52 \pm 0.25	0.88 \pm 0.18	0.17 \pm 0.03
1 h	1.20 \pm 0.14	0.52 \pm 0.18	7.84 \pm 0.79	1.69 \pm 0.23	0.46 \pm 0.04	0.37 \pm 0.06
4 h	1.08 \pm 0.11	0.37 \pm 0.16	4.28 \pm 0.19	1.35 \pm 0.27	0.14 \pm 0.07	0.09 \pm 0.01
24 h	0.09 \pm 0.02	-	0.85 \pm 0.08	0.27 \pm 0.10	-	0.05 \pm 0.01

Supplementary Table 3. Quantitative determination of liver, kidney, and pancreas profile markers in lithium-heparinized whole blood from NSG mice (n=4).

Marker	Single dose study			Multiple dose study				GDC-0449 + let-7b micelles treated mice
	Untreated mice	Emulsion treated mice	Micelles treated mice	Control mice	GDC-0449 micelles treated mice	let-7b micelles treated mice		
ALB (g/dL)	3.27	2.77	3.25	2.6	3.0	2.8	2.6	
ALP (U/L)	22.33	21.0	26.75	30.0	30.3	22.0	25.6	
ALT (U/L)	36.33	28.25	21.75	66.3	46.0	26.7	38.4	
AMY (U/L)	740.6	979.7	762.2	-	-	-	-	
TBIL (mg/dL)	0.30	0.25	0.27	0.30	0.30	0.30	0.28	
BUN (mg/dL)	19.67	19.25	18.75	20.0	18.0	17.7	19.61	
Ca+ (mg/dL)	4.00	9.87	4.00	9.9	9.9	9.8	9.7	
PHOS mg/dL	5.57	10.15	6.05	-	-	-	-	
CRE (mg/dL)	0.20	0.25	0.20	0.3	0.2	0.2	0.2	
GLU (mg/dL)	196.33	159.5	187.5	123.3	128.7	179.7	167.2	
Na+ (mmol/L)	160.33	147.75	151.75	149.0	149.7	147.7	158.3	
K+ (mmol/L)	10.83	5.77	9.37	3.6	5.8	6.0	5.9	
TP (g/dL)	4.90	4.45	4.95	4.1	4.4	4.5	4.3	
GLOB (g/dL)	1.6	1.7	1.7	1.4	1.4	1.7	1.6	

Markers: Albumin (ALB), Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Amylase (AMY), Total Bilirubin(TBIL), Urea Nitrogen (BUN), Calcium (CA), Phosphorus (PHOS), Creatinine (CRE), Glucose (GLU), Sodium (Na+), Potassium (K+), Total Protein (TP), Globulin (GLOB)